Skip to main content

Current & emerging therapies for the management of patients with endometrial cancer

Published on July 30, 2026   42 min

A selection of talks on Cancer

Please wait while the transcript is being prepared...
0:00
Good day. My name is Dr. Brian Slomovitz. I'm the Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, and I also serve as a Professor of Obstetrics and Gynecology at the Florida International University. I'm also a member of the board of directors of the GOG Foundation, and I am the clinical trial lead for the GOG Partners in endometrial cancer. Today, I'll be discussing current and emerging therapies for the management of patients with endometrial cancer.
0:32
Here are my disclosures.
0:35
Endometrial cancer is the only gynecologic cancer with a rising incidence and mortality. Amazingly, the number of deaths due to endometrial cancer now exceeds the number of deaths due to ovarian cancer, which had traditionally been known as the silent killer. When we look at endometrial cancer, we consider that two-thirds of them are what I like to call won and done. We get a biopsy. We identify a cancer, and these patients are treated with a hysterectomy, require no further therapy, and go on and live a long, healthy life without worrying about their disease. It's the one-third of the cases who have advanced or recurrent disease that account for the high rising death rate due to endometrial cancer. This represents the unmet need to where we need to get better treatment options.
1:25
One thing that's nice about endometrial cancer over the last decade is that we've really changed from looking at light microscopy to more molecular microscopic makeup of tumor classification. As I go forward, I'll describe further.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Current & emerging therapies for the management of patients with endometrial cancer

Embed in course/own notes